Results 131 to 140 of about 1,498,446 (168)
Some of the next articles are maybe not open access.
REVERSAL OF SOME THERAPEUTIC EFFECTS OF AN ANTIPSYCHOTIC AGENT BY AN ANTIPARKINSONISM DRUG
The Journal of Nervous and Mental Disease, 1973Data are presented from a multidimensional, longitudinal study in 10 acute schizophrenics which indicate that the addition of benztropine to haloperidol reversed the course of some of the therapeutic changes. The nontherapeutic interaction was selective involving what may be called social avoidance behavior but not the cognitive integrative ...
M M, Singh, J M, Smith
openaire +2 more sources
Metabolism of antiparkinson agent dopazinol by rat liver microsomes.
Drug Metabolism and Disposition, 1990Metabolism of dopazinol (DZ) by liver microsomes from control and phenobarbital- and 3-methylcholanthrene-treated rats has been investigated. Liver microsomes from control and treated rats metabolized DZ to N-despropyl-DZ (39-53% of total metabolites); 8-hydroxy-DZ, a catechol metabolite (32-39%); and 5- or 6-hydroxy-DZ (12-20%).
K P, Vyas +4 more
openaire +2 more sources
[Phenibut potentiation of the therapeutic action of antiparkinson agents].
Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1986It was observed in experiments on mice that the central action of phenibut (beta-phenyl-gamma-aminobutyric acid) diminished after destruction of brain dopaminergic neurons by 6-hydroxydopamine and after pretreatment with the dopamine receptor blocker haloperidol which suggests the dopaminergic component in the action of phenibut.
Iu V, Gol'dblat, I P, Lapin
openaire +1 more source
Nederlands tijdschrift voor geneeskunde, 1987
A L, Staal-Schreinemachers, J P, Lakke
openaire +3 more sources
A L, Staal-Schreinemachers, J P, Lakke
openaire +3 more sources
Potential antiparkinsonism agents. Quinuclidinyl benzhydryl ethers
Journal of Medicinal Chemistry, 1969J L, Nilsson, J, Wågermark, R, Dahlbom
openaire +2 more sources